UNC Researchers Involved in Experimental COVID-19 Treatment Now Moving to Human Trials

CHAPEL HILL – All hands are on deck for innovative treatments and tests for SARS-CoV2 and the COVID-19 it causes, and researchers from the University of North Carolina are no exception. A team from UNC is involved in the development of an antiviral drug that shows promise of reducing severe lung damage caused by the respiratory virus. The study is now expected to move to human trials in the spring.

The drug is called EIDD-2801 for now. The senior author of the drug study is a Ralph Baric the William R. Kenan Jr. Distinguished Professor of epidemiology at UNC Chapel Hill.

Trending: CNBC/Change Research Poll Shows Cooper’s Fast-Sinking Approval Numbers Over Recent Weeks, Now Underwater

“This new drug not only has high potential for treating COVID-19 patients, but also appears effective for the treatment of other serious coronavirus infections.” Epidemiologist Ralph Baric

take our poll - story continues below

Do you think Roy Cooper should reopen North Carolina?

  • URGENT COVID POLL: Do you think Roy Cooper should reopen North Carolina?  

  • This field is for validation purposes and should be left unchanged.
Completing this poll grants you access to First In Freedom Daily updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

With any luck, this is one of several viable and effective treatments for COVID-19 to be developed in the coming weeks and months. A vaccine is not expected to be available for the novel virus for another year or more.

You can read the full study (bring a medical dictionary) from the researchers here.

Have a hot tip for First In Freedom Daily?

Got a hot news tip for us? Photos or video of a breaking story? Send your tips, photos and videos to tips@firstinfreedomdaily.com. All hot tips are immediately forwarded to FIFD Staff.

Have something to say? Send your own guest column or original reporting to submissions@firstinfreedomdaily.com.